-transparent.png){kind=logo}
Clinical surveys have indicated the predominance of type 5 and type 8 capsular polysaccharides among clinical isolates of Staphylococcus aureus. The type 5 capsular polysaccharide was extracted from three clinical isolates of S. aureus grown on solid media, and purified by ion exchange chromatography and gel filtration. Chemical analysis showed that the type 5 capsular polysaccharide is composed of N-acetylfucosamine and N-acetylhexosaminuronic acid. Immunodiffusion and 13C nuclear magnetic resonance experiments showed that the type 5 capsular polysaccharide is both immunologically and chemically distinct from the type 8 capsular polysaccharide and the teichoic acid of S. aureus.
J M Fournier, and
K Hannon, and
M Moreau, and
W W Karakawa, and
W F Vann
July 1990,
Carbohydrate research,
J M Fournier, and
K Hannon, and
M Moreau, and
W W Karakawa, and
W F Vann
March 2010,
Infection and immunity,
J M Fournier, and
K Hannon, and
M Moreau, and
W W Karakawa, and
W F Vann
October 1987,
Journal of clinical microbiology,
J M Fournier, and
K Hannon, and
M Moreau, and
W W Karakawa, and
W F Vann
August 1994,
Journal of bacteriology,
J M Fournier, and
K Hannon, and
M Moreau, and
W W Karakawa, and
W F Vann
October 1998,
Infection and immunity,
J M Fournier, and
K Hannon, and
M Moreau, and
W W Karakawa, and
W F Vann
March 1994,
Vaccine,
J M Fournier, and
K Hannon, and
M Moreau, and
W W Karakawa, and
W F Vann
February 1991,
Applied and environmental microbiology,
J M Fournier, and
K Hannon, and
M Moreau, and
W W Karakawa, and
W F Vann
July 1984,
Infection and immunity,
J M Fournier, and
K Hannon, and
M Moreau, and
W W Karakawa, and
W F Vann
July 2002,
Infection and immunity,
J M Fournier, and
K Hannon, and
M Moreau, and
W W Karakawa, and
W F Vann
May 1991,
Journal of general microbiology,
